Company intelligence / Profile preview
Moleculin Biotech, Inc.
Houston, Texas, United Statesmoleculin.com ↗
- Ownership
- Public · MBRX
- Development stage
- Phase 3
01
Overview
Moleculin is advancing Annamycin, a next-generation anthracycline now called naxtarubicin, into a pivotal adaptive Phase 3 trial (“MIRACLE” trial) for relapsed/refractory AML. Preliminary data from prior studies show durable complete responses with reduced cardiotoxicity compared to traditional anthracyclines. Additional pipeline assets include immune/transcription modulators targeting STAT3-driven cancers and antimetabolites for both oncology and viral indications. Initial data readout from the MIRACLE trial is expected in the second half of 2025.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules (notably anthracyclines and antimetabolites)Immune/transcription modulators
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships publicly disclosed as of May 2025. The company collaborates with academic institutions for research purposes.
04
Financials
- Market cap
- $8.9M
- Total revenue
- $0
- Enterprise value
- $1.9M
Beyond the preview
Go deeper on Moleculin Biotech, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Moleculin Biotech, Inc..